Polpharma named National Champion

09.04.2018 News

Polpharma named National Champion

Polpharma took 6th place in the National Champion ranking by Polityka Insight. The ranking was published in a report entitled “National Champions. What are the ones Poland needs?”

The authors of the report have adopted the following definition of a national champion:

The main feature shared by national champions is their importance for the economy. National champions drive business growth and shape the country's image abroad. They are highly active on the international scene, enjoy oligopolistic or even monopolistic position in the industry, and are prepared to finance research and innovation.

Polpharma took the high 6th place in the ranking, behind such giants as KGHM, PKN Orlen, PGNIG, Ciech and Synthos. The top ten companies also included: Asseco, Comarch, Azoty and Boryszew.

The following criteria were taken into account: the significance of the company for the Polish economy, its position in the industry, its international presence and its level of innovation.

Polpharma took a very high third place in the “innovation” category, ahead of PKN Orlen, Synthos and Energa. In terms of international presence, Polpharma ranked 5th, leaving behind the overall winner, KGHM.

The report was officially announced in Warsaw on 9 April, with Minister of Entrepreneurship and Technology Jadwiga Emilewicz attending the event. The National Champions took part in a panel after the presentation of the report. Among the speakers were: President of the Polish Development Fund Paweł Borys, President of the Polish Agency for Investment and Trade Tomasz Pisuła, President of Polpharma Markus Sieger and Vice-President of Asseco Artur Wiza.

“As an important partner in the Polish economy, Polpharma has driven economic growth with its expertise and state-of-the-art technology. Our greatest asset as a National Champion is innovation. We are constantly investing in new products needed by patients. In 2017, our Group invested 11.4% of its revenues in research and development. In 2018, this figure will rise to almost 14%,” said President of Polpharma.

go back